Company news

electroCore, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

electroCore Announces Pricing of $18.0 Million Public Offering of Common Stock

June 29, 2021

electroCore Announces Proposed Public Offering of Common Stock

June 28, 2021

electroCore Announces Publication of Study on the Effect of non-invasive Vagus Nerve Stimulation (nVNS) on Cognitive Performance Caused by Sleep Deprivation

June 23, 2021

electroCore, Inc. Announces Exclusive Distribution Agreement with Kromax For Taiwan and China

June 22, 2021

electroCore Completes Sale of $1.4 Million of NJ NOL Tax Benefits

June 8, 2021

electroCore Announces Publication of Study on Non-Invasive Vagus Nerve Stimulation (nVNS) to Improve Clinical Outcomes and Molecular Biomarkers in Parkinson’s Disease Patients

June 1, 2021

electroCore Announces First Quarter 2021 Financial Results

May 5, 2021

electroCore, Inc. Announces U.S. Department of Veterans Affairs Study of gammaCore Sapphire™ (Non-Invasive Vagus Nerve Stimulator) for the Treatment of Post-Traumatic Headache

May 3, 2021

electroCore to Announce First Quarter 2021 Financial Results on Thursday, May 6

April 28, 2021

electroCore, Inc. Announces Johns Hopkins University School of Medicine Study of Non-Invasive Vagus Nerve Stimulation (nVNS) for Symptomatic Exacerbation of Nausea in Patients with Gastroparesis and Related Disorders

April 25, 2021

electroCore, Inc. Announces Exclusive Distribution Agreement with East Agency For Qatar

April 19, 2021

electroCore Provides Business Update and Select First Quarter 2021 Financial Guidance

April 12, 2021

electroCore Announces Top Line Results from SAVIOR-1 study of Non-Invasive Vagus Nerve Stimulation (nVNS) in Hospitalized COVID-19 Patients

April 7, 2021

electroCore, Inc. Announces Regulatory Approval in Canada

April 4, 2021

electroCore, Inc. Announces Exclusive Distribution Agreement with Silvert Medical Nv-Sa. For Western Europe

March 22, 2021

electroCore Announces Fourth Quarter and Full Year 2020 Financial Results

March 10, 2021

electroCore to Announce Fourth Quarter and Year Ended December 31, 2020 Financial Results on Thursday, March 11

March 3, 2021

electroCore Inc. Announces Exclusive Distribution Agreement with Medistar Following Regulatory Approval in Australia

February 27, 2021

electroCore Announces Two-Year Extension of gammaCore™ Listing in the NHS Supply Chain Catalogue

February 22, 2021

electroCore Announces 510(k) Clearance of gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) to Treat Adolescent Migraine

February 15, 2021

electroCore Announces Completion of Enrollment in SAVIOR-1 Study of Non-Invasive Vagus Nerve Stimulation (nVNS) in COVID-19 Patients Exhibiting Respiratory Symptoms

February 10, 2021

electroCore Announces Publication of Study on Non-Invasive Vagus Nerve Stimulation (nVNS) to Reduce Ileus After Major Colorectal Surgery

February 8, 2021

electroCore Announces Full Enrollment of TR-VENUS study of Non-Invasive Vagal Nerve Stimulation (nVNS) for the Acute Treatment of Stroke

February 1, 2021

electroCore, Inc. Announces Inclusion of gammaCore Sapphire™ in new NHS England and NHS Improvement MedTech Funding Mandate Policy 2021/22

January 26, 2021

electroCore, Inc. Announces Exclusive Distribution Agreement with RSK Medical Inc. in Canada

January 25, 2021

electroCore, Inc. Announces Scottish Health Technology Group Recommendation For Use of gammaCore™ in NHS Scotland Cluster Headache Patients

January 20, 2021

electroCore, Inc. Announces the Establishment of a Unique Level II HCPCS Code for “Non-Invasive Vagus Nerve Stimulator”

January 18, 2021

electroCore, Inc. Announces Agreement with Pro Medical Baltic to be Exclusive Distributor for gammaCore Sapphire™ in Eastern Europe

December 20, 2020

electroCore Announces Positive Top-Line Results from PREMIUM II Migraine Prevention Study

December 7, 2020

electroCore Announces Selection of gammaCore for National Institute on Drug Abuse (NIDA)-Sponsored Study in Opioid Use Disorders

November 30, 2020

electroCore Announces Third Quarter Financial Results

November 11, 2020

electroCore, Inc. Appoints Business Development Leader and US Navy Veteran Sylvester Steele as VP and General Manager of Government Channels Business Unit

October 20, 2020

electroCore, Inc. Announces Extension of NHS England’s Innovation and Technology Payment (ITP) Program to Fund Continued Use of gammaCore™ in England

September 30, 2020

electroCore Announces Department of Veterans Affairs Sponsored Study of Non-Invasive Vagal Nerve Stimulation (nVNS) in Mild Traumatic Brain Injury (mTBI) and Post-Traumatic Stress Disorder (PTSD)

September 29, 2020

electroCore Announces Agreement with UpScript, LLC to be Exclusive Online Telehealth Provider for gammaCore Sapphire™ CV

September 23, 2020

electroCore Announces Publication in Brain Stimulation Highlighting Non-Invasive Vagal Nerve Stimulation’s (nVNS) Potential Role in Treatment of Post-Traumatic Stress Disorder (PTSD)

August 26, 2020

electroCore, Inc. Announces Publication of a Voluntary ex-ante Transparency Tender Notice Award by NHS England to Fund Continued Use of gammaCore™ in England

August 23, 2020

electroCore Announces Second Quarter Financial Results

August 12, 2020

electroCore Provides Update on Availability of gammaCore Sapphire™ CV for the Acute Treatment of Asthma Exacerbations in Known or Suspected COVID-19 Patients

July 29, 2020

electroCore Announces Non-Invasive Vagus Nerve Stimulation Clinical Update Publication in Cephalalgia

July 27, 2020

electroCore Provides Business Update and Select Financial Guidance

July 13, 2020

electroCore Announces FDA Emergency Use Authorization for use of gammaCore Sapphire™ CV for the Acute Treatment of Asthma Exacerbations in Known or Suspected COVID-19 Patients

July 12, 2020

← Newer news releases

Calls

The 5 newest of 23 calls. Every call is listed under its year.

Decks

The 5 newest of 14 decks. Every deck is listed under its year.